PRDM1 and breast cancer: Thus, ex-vivo approach was used to investigate IL-2 anti-tumor effect on breast cancer cells isolated from Egyptian patients after mastectomy via modulating Treg/CTLA-4/Blimp-1/caspase-3 trajectory.